van Hest RM - Search Results

1

Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA. Preijers T, et al. Among authors: van hest rm. Ther Drug Monit. 2019 Apr;41(2):192-212. doi: 10.1097/FTD.0000000000000625. Ther Drug Monit. 2019. PMID: 30883513 Review.

2

Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?

van Gelder T, Hesselink DA, van Hest RM, Mathôt RA, van Schaik R. van Gelder T, et al. Among authors: van hest rm, van schaik r. Ther Drug Monit. 2004 Aug;26(4):343-6. doi: 10.1097/00007691-200408000-00001. Ther Drug Monit. 2004. PMID: 15257061 Review. No abstract available.

3

Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy.

van Hest RM, Mathôt RA, Vulto AG, Le Meur Y, van Gelder T. van Hest RM, et al. Among authors: van gelder t. Ther Drug Monit. 2004 Dec;26(6):620-5. doi: 10.1097/00007691-200412000-00006. Ther Drug Monit. 2004. PMID: 15570185

4

Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation.

van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T. van Hest R, et al. Ther Drug Monit. 2005 Apr;27(2):163-7. doi: 10.1097/01.ftd.0000158083.45954.97. Ther Drug Monit. 2005. PMID: 15795646

5

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T. Hesselink DA, et al. Among authors: van gelder t, van hest rm. Am J Transplant. 2005 May;5(5):987-94. doi: 10.1046/j.1600-6143.2005.00779.x. Am J Transplant. 2005. PMID: 15816878 Free article.

6

Population pharmacokinetics of mycophenolic acid in renal transplant recipients.

van Hest RM, van Gelder T, Vulto AG, Mathot RA. van Hest RM, et al. Among authors: van gelder t. Clin Pharmacokinet. 2005;44(10):1083-96. doi: 10.2165/00003088-200544100-00006. Clin Pharmacokinet. 2005. PMID: 16176120

7

Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view.

van Hest RM, Mathot RA, Vulto AG, Ijzermans JN, van Gelder T. van Hest RM, et al. Among authors: van gelder t. Ther Drug Monit. 2006 Feb;28(1):31-4. doi: 10.1097/01.ftd.0000194504.62892.b2. Ther Drug Monit. 2006. PMID: 16418690 Review.

8

Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.

van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. van Hest RM, et al. Among authors: van gelder t. J Am Soc Nephrol. 2006 Mar;17(3):871-80. doi: 10.1681/ASN.2005101070. Epub 2006 Feb 1. J Am Soc Nephrol. 2006. PMID: 16452491

9

Individualization of mycophenolate mofetil dose in renal transplant recipients.

van Hest RM, Hesselink DA, Vulto AG, Mathot RA, van Gelder T. van Hest RM, et al. Among authors: van gelder t. Expert Opin Pharmacother. 2006 Mar;7(4):361-76. doi: 10.1517/14656566.7.4.361. Expert Opin Pharmacother. 2006. PMID: 16503809 Review.

10

Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?

de Winter BC, Mathôt RA, van Hest RM, van Gelder T. de Winter BC, et al. Among authors: van gelder t, van hest rm. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):251-61. doi: 10.1517/17425255.3.2.251. Expert Opin Drug Metab Toxicol. 2007. PMID: 17428154 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters